Differences in tissue drug concentrations following intravenous versus intraperitoneal treatment with amphotericin B deoxycholate or liposomal amphotericin B

Medical Mycology

Volumn 48, Issue 2, 2010, Pages 430-435

  Chang, T ^a   Olson, J A ^a   Proffitt, R T ^b   Adler Moore, J P ^a  

^a CALIFORNIA STATE POLYTECHNIC UNIVERSITY   (United States)

^b RichPro Associates   (United States)

Author keywords

Amphotericin B; Drug concentrations; Intraperitoneal; Intravenous; Liposomal amphotericin B

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; AMPHOTERICIN B; AMPHOTERICIN B, DEOXYCHOLATE DRUG COMBINATION; ANTIFUNGAL AGENT; DEOXYCHOLIC ACID; DRUG COMBINATION;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIMICROBIAL THERAPY; ARTICLE; BIOASSAY; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG LIVER LEVEL; DRUG PENETRATION; DRUG RETENTION; DRUG TISSUE LEVEL; FEMALE; KIDNEY; LUNG; MOUSE; NONHUMAN; PAECILOMYCES; PLASMA CLEARANCE; SPLEEN; TISSUE DISTRIBUTION; TISSUE SECTION; ANIMAL; BLOOD; COMPARATIVE STUDY; DRUG COMBINATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER; METABOLISM; NONPARAMETRIC TEST;

MUS;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; LIVER; MICE; STATISTICS, NONPARAMETRIC; TISSUE DISTRIBUTION;

EID: 76649098523     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903208249     Document Type: Article

References (24)

1. Adler-Moore J, Proffitt RT. Am Bisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49 ( Suppl. A ): 21-30 .
2. Adler-Moore JP, Proffitt RT. Amphotericin Blipid preparations: what arethe differences? Clin Microbiol Infect 2008; 14:( Suppl. 4): 25-36 .
3. Lanternier F, Lortholary O.. Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 2008; 14: ( Suppl. 4 ): 71-83.
4. Cordonnier C, Mohty M, Faucher C, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008; 31: 135-141.
5. Adler-Moore JP, Olson JA, Proffitt RT. Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis. J Antimicrob Chemother 2004; 54: 1096-1102 .
6. Clemons KV, Stevens DA. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr Opin Infect Dis 2006; 19: 360-364 .
7. Olson JA, Adler-Moore JP, Smith PJ, et al.. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Antimicrob Agents Chemother 2005; 49: 4895-4902 .
8. Ortoneda M, Capilla J, Pastor FJ, et al.. Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin Bin thetreatment of systemic murine scedosporiosis. Diagn Microbiol Infect Dis 2004; 50: 247-251 .
9. Graybill JR, Bocanegra R. Liposomal amphotericin B therapy of murine histoplasmosis. Antimicrob Agents Chemother 1995; 39: 1885-1887 .
10. Shadomy S, McCay JA, Schwartz SI, et al. Bioassay for hamycin and amphotericin Bin serum and other biological fluids. Appl Microbiol 1969; 17: 497-503 .
11. Smith PJ, Olson JA, Constable D, et al.. Effects of dosing regimen on accumulation, retention and prophylactic Efficacy of liposomal amphotericin B. J Antimicrob Chemother 2007; 59: 941-951 .
12. Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin Bin treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infect. J Infect Dis 1994; 169: 356-368 .
13. Murphy K , Travers P , Walport M. Chapter 1: Basic Concepts in Immunology . Janeway's Immunobiology. 7th edn . New York : Garland Science , 2008 .
14. Kirby C, Clarke J, Gregoriadis G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro . Biochem J 1980; 186: 591-598 .
15. Hirano K, Hunt CA. Lymphatic transport of liposome-encapsulated agents: effects of liposome size following intraperitoneal administration. J Pharm Sci 1985; 74: 915-921 . (Pubitemid 15014130)
16. Adler-Moore JP, Proffitt RT. Development, characterization, Efficacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Lip Res 1993; 3: 429-450 .
17. Bekersky I, Fielding RM, Dressler DE, et al. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate. Antimicrob Agents Chemother 2002; 46: 834-840 .
18. Abra RM, Hunt CA. Liposome disposition in vivo , III: dose and vesicle-size effects. Biochem. Biophys Acta 1981; 666: 493-503 .
19. Groll AH, Lyman CA, Petraitis V, et al. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob Agents Chemother 2006; 50: 3418-3423 .
20. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin Bin a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45: 922-926 .
21. Andes D, Safdar N, Marchillo K, et al. Pharmacokineticpharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMBlipid complex, in murine candidiasis models. Antimicrob Agents Chemother 2006; 50: 674-684 .
22. Goodman JS, Koenig MG. Amphotericin B - specifics of administration. Mod Treat 1970; 7: 581-595 .
23. Olson JA, Adler-Moore JP, Schwartz J, et al. Comparative effi cacies, toxicities, and tissue concentrations of amphotericin Blipid formulations in a murine pulmonary aspergillosis model. Antimicrob Agents Chemother 2006; 50: 2122-2131 .
24. Olson JA, Adler-Moore JP, Jensen GM, et al.. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother 2008; 52: 259-268 .